These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension. Heidari Nejad S; Azzam O; Schlaich MP Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184 [TBL] [Abstract][Full Text] [Related]
6. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Miyagawa K; Emoto N Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369 [TBL] [Abstract][Full Text] [Related]
7. Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis. Yuan W; Cheng G; Li B; Li Y; Lu S; Liu D; Xiao J; Zhao Z Blood Press; 2017 Jun; 26(3):139-149. PubMed ID: 27808564 [TBL] [Abstract][Full Text] [Related]
8. Update on Endothelin Receptor Antagonists in Hypertension. Burnier M Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164 [TBL] [Abstract][Full Text] [Related]
9. Endothelin Receptor Antagonists: New Hope for Renal Protection? Tobe S; Kohan DE; Singarayer R Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelin in hypertension. Schiffrin EL Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745 [TBL] [Abstract][Full Text] [Related]
11. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists. Heidari Nejad S; Azzam O; Schlaich MP Future Cardiol; 2024; 20(9):435-445. PubMed ID: 38953510 [TBL] [Abstract][Full Text] [Related]
12. From ABCD to E for endothelin in resistant hypertension. Abraham GR; Davenport AP Cell; 2023 Jan; 186(2):240-242. PubMed ID: 36603580 [TBL] [Abstract][Full Text] [Related]
13. Endothelin in hypertension. Schiffrin EL Curr Opin Cardiol; 1995 Sep; 10(5):485-94. PubMed ID: 7496057 [TBL] [Abstract][Full Text] [Related]
14. Endothelin antagonists and resistant hypertension in chronic kidney disease. Moore R; Linas S Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):432-6. PubMed ID: 20502329 [TBL] [Abstract][Full Text] [Related]
15. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. El-Mas MM; Helmy MW; Ali RM; El-Gowelli HM Toxicol Appl Pharmacol; 2015 Apr; 284(1):1-7. PubMed ID: 25656942 [TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies. Reichetzeder C; Tsuprykov O; Hocher B Life Sci; 2014 Nov; 118(2):141-8. PubMed ID: 24607774 [TBL] [Abstract][Full Text] [Related]
17. Endothelin in hypertension: a role for receptor antagonists? Moreau P Cardiovasc Res; 1998 Sep; 39(3):534-42. PubMed ID: 9861294 [TBL] [Abstract][Full Text] [Related]
18. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females. Gillis EE; Sasser JM; Sullivan JC Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R691-6. PubMed ID: 26936781 [TBL] [Abstract][Full Text] [Related]
19. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. Goddard J; Webb DJ Drugs R D; 1999 Jul; 2(1):1-12. PubMed ID: 10560541 [TBL] [Abstract][Full Text] [Related]
20. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Enseleit F; Lüscher TF; Ruschitzka F Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):231-40. PubMed ID: 20660536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]